ЭКЛЕСТОН Марк (GB),ВЕЙНИККА Сату (GB),МОРРИС Джордж Стивен (GB)
申请号：
RU2014122158/10
公开号：
RU2014122158A
申请日:
2012.11.01
申请国别(地区):
RU
年份:
2015
代理人:
摘要：
1. A molecule that inhibits or prevents the interaction between the kinase of the Src family and the androgen receptor (AR) or estradiol receptor (ER) for use in the prevention and treatment of non-cancerous diseases, in the development of which the subject plays the role of AR and / or ER, or use in the prevention or treatment of cancer, in the development of which the role of the activity of AR and / or ER in a subject who wants to maintain fertility, or for use in the prevention or treatment of gynecological disease, is developed and played the role of AP and / or ER.2. The use of a molecule that inhibits or prevents the interaction between the kinase of the Src family and the androgen receptor (AR) or estradiol receptor (ER), for the manufacture of a medicament for the prevention or treatment of non-cancerous disease, in the development of which the activity of AR and / or ER, or prevention or for treating a cancer, in the development of which the activity of AR and / or ER plays a role in a subject who wants to maintain fertility, or for the prevention or treatment of a gynecological disease, in the development of which It plays the role of AR activity and / or ER.3. A method for the prevention or treatment of a non-cancerous disease, in the development of which the activity of the androgen receptor (AR) and / or the estradiol receptor (ER) plays a role, or the prevention or treatment of a cancer, in the development of which the activity of the AR and / or ER plays a role in a subject who wishes to maintain fertility, or prophylaxis or treatment of a gynecological disease, in the development of which the activity of AR and / or ER plays a role, where the method includes iv1. Молекула, которая ингибирует или предотвращает взаимодействие между киназой семейства Src и андрогенным рецептором (АР) или рецептором эстрадиола (ЭР) для применения в профилактике и лечении нераковых заболеваний, в развитии которых у субъекта играет роль активность АР и/или ЭР, или для при
